FDA WEEKLY INTELLIGENCE • ASIAN MEDTECH & PHARMA TRACKER

FDA Weekly Report — Week 28, 2026

Coverage: 2026-06-26 – 2026-07-02 (FDA publish date basis)

Published: July 11, 2026

Note: FDA typically publishes approvals 1–2 weeks after decision date. This report reflects the latest available data as of publication.

This Week at FDA

This week's FDA activity was defined by a quiet period for novel drugs, contrasted by robust developments in medical devices and label expansions. The sole new drug approval was the New Molecular Entity LUMVOA (veligrotug), while five successful efficacy supplements highlight the continued industry focus on lifecycle management to expand market access for existing assets. A high volume of device clearances, including five original PMAs for high-risk products, indicates sustained innovation in medtech, and significant activity from Asian-based firms underscores their expanding role in the US regulatory landscape. No significant Warning Letters were identified within this week's reporting scope.

1	1	5	203	5
NME Approvals	Total Drug Approvals	New Indications	510(k) Clearances	PMA Originals

64

Asian Co. Events

🌏 Asian Company Watch — FDA Activity This Week

Asian companies with FDA approvals or clearances this week. The highest-priority items below include strategic commentary on what it means for the competitive landscape; the remaining approvals are listed for completeness (full detail for every item is available in the accompanying Excel data set). Country classification is based on ultimate corporate group origin, not necessarily the filing legal entity's place of incorporation (e.g. a US-registered subsidiary of a Japanese parent group is classified as Japanese).

🇰🇷 Honeynaps Co., Ltd. South Korea

SOMNUM (SOMNUM)

🇨🇳 Shenzhen Changkun Technology Co., Ltd. China

Electric breast pump (6 models)

🇨🇳 Ziree Co., Ltd. China

Laser Hair Growth Devices (15 models)

🇨🇳 Shenzhen Dongdixin Technology Co., Ltd. China

TENS 7000 Rechargeable 4 Channel

🇨🇳 Vistar Medical Supplies Co., Ltd. China

DVT Garment

🇰🇷 Seers Technology Co., Ltd. South Korea

mobiCARE Cardiac Monitoring System (4 models)

🇨🇳 Weyo Surgical Technology, Ltd. China

Insufflator (6 models)

🇨🇳 **Shenzhen Mindray Bio-Medical Electronics Co., Ltd.** China

A5 Anesthesia System

🇨🇳 **Shenzhen Qinyi Electronic Technology Co., Ltd.** China

Wearable breast pump (3 models)

🇨🇳 **Shanghai Waylong Intelligent Technology Co., Ltd.** China

Smart Electric Wheelchair (4 models)

🇨🇳 **Hangzhou Jimushi Meditech Co., Ltd.** China

Hydrophilic coated intermittent nalaton...

🇯🇵 **Olympus Medical Systems Corporation** Japan

HD Camera Head OLYMPUS CH-S200-08-LB

🇨🇳 **Hangzhou AGS MedTech Co., Ltd.** China

Single-use Balloon Dilatation Catheter...

🇰🇷 **CG Bio Co., Ltd.** South Korea

CURASYS 2 (EMDN0003)

🇹🇼 **Microlife Corporation** Taiwan

Microlife Digital Peak Flow Meter, Model PF200B

🇨🇳 **Guangdong Yong Yi Rehabilitation Equipment Technology Co., Ltd.**

China

> Caregiver-assisted wheelchair

🇨🇳 **Guangdong Yong Yi Rehabilitation Equipment Technology Co., Ltd.**

China

> Manual Wheelchair

🇨🇳 **Shenzhen Ziqing Medical Equipment Co., Ltd.** China

> Wrist Blood Pressure Monitor (XW-05)

🇨🇳 **Shantou Institute of Ultrasonic Instruments Co., Ltd.** China

> Portable DR Imaging System

🇨🇳 **Shenzhen Konmed Technology Co., Ltd.** China

> Pelvic Muscle Trainer (KM510, KM516B)

🇨🇳 **Zhejiang Innuovo Rehabilitation Devices Co., Ltd.** China

> Power Wheelchair (3 models)

🇰🇷 **MegaGen Implant Co., Ltd.** South Korea

> MegaGen Zygoma Dental Implant System

🇨🇳 **Micro-Energy Medical Technology Co., Ltd.** China

> Hemolase Fiber

🇰🇷 **GC America, Inc.** South Korea

SRGC-06

🇨🇳 **Suzhou and Science & Technology Development Corp.** China

AND Medical Femoral Nail System

🇰🇷 **Vieworks Co., Ltd.** South Korea

VIVIX-S 4386W (FXRD-4386WA)

🇨🇳 **Guangzhou Rebornendo Medical Instrument Co., Ltd.** China

Curing Light (M-Cure 6)

🇯🇵 **FUJIFILM Healthcare Americas Corporation** Japan

Synapse PACS (7.6.0)

🇨🇳 **Guangdong Newdermo Biotech Co., Ltd.** China

LED Light Therapy Mask (6 models)

🇨🇳 **Shenzhen Root Innovation Technology Co., Ltd.** China

Momcozy Wearable Breast Pump (5 models)

🇹🇼 **Oneness Biotech Co., Ltd.** Taiwan

Bonvadis®

🇨🇳 **Shenzhen Root Innovation Technology Co., Ltd.** China

Momcozy Wearable Breast Pump (5 models)

🇨🇳 **Hua Yue Medical Technology Co., Ltd.** China

> Assisted Reproduction Laser System

🇨🇳 **Beijing Fule Science & Technology Development Co., Ltd.** China

> Fule Metallic Lockable Intramedullary...

🇨🇳 **Foshan Pingchuang Medical Technology Co., Ltd.** China

> Non-Sterile Ultrasound Gel; Sterile...

🇹🇼 **Socko Medical Co., Ltd.** Taiwan

> “Socko” Vimax Spinal Fixation System

🇨🇳 **Honsun (Nantong) Co., Ltd.** China

> Portable Oxygen Concentrator

🇨🇳 **Shenzhen Kaiyan Medical Equipment Co., Ltd.** China

> LED Neck Beauty Mask (4 models)

🇨🇳 **Zdeer Technology (Henan) Co., Ltd.** China

> Laser Hair Growth Device (9 models)

🇨🇳 **Hubei Yjt Technology Co., Ltd.** China

> Laser Hair Growth System (5 models)

🇨🇳 **Zhejiang Decans Medical Devices Co., Ltd.** China

> HERA Interlocking Intramedullary...

🇹🇼 Hivox Biotek, Inc. Taiwan

TENS / EMS DEVICE (2 models)

🇯🇵 Fujifilm Corporation Japan

FUJIFILM Endoscope Model EB-840S;...

🇨🇳 Hunan Ruijiong Biotech Co., Ltd. China

KT Airway Clearance Device II

🇰🇷 Medpark Co., Ltd. South Korea

BOSS

🇰🇷 Crescom Co., Ltd. South Korea

MediAI-OA

🇨🇳 Zhongshan Sulenz Intelligent Technology Co., Ltd. China

Electric Wheelchair (S500-6)

🇨🇳 Zdeer Technology (Henan) Co., Ltd. China

Bone Conduction Hearing Aid (38 models)

🇰🇷 Medyssey Co., Ltd. South Korea

NeckTune™ 3D SA Cervical Cage

🇨🇳 Beijing Fule Science & Technology Development Co., Ltd. China

Fule Interbody Fusion Cage System

🇰🇷 JPI Healthcare Co., Ltd. South Korea

DRE Duo

🇨🇳 Gimbo Medical Technology Shenzhen Co., Ltd. China

Giftlife Single Lumen Oocyte Retrieval...

🇰🇷 LG Electronics Inc. South Korea

Medical Monitor (40HT513D)

🇨🇳 Sanhe LEFIS Electronics Co., Ltd. China

Intense Pulsed Light Therapy Device

🇯🇵 Whill, Inc. Japan

WHILL (WHILL Model C2)

🇰🇷 Dyne Medical Group, Inc. South Korea

DYNE PORT

🇨🇳 Polybell (Guangzhou) Limited China

Electric Breast Pump (13 models)

🇨🇳 SteriLance Medical (Suzhou), Inc. China

Disposable Blood Lancet (Soft)

🇨🇳 Changzhou Boen Zhongding Medical Technology Co., Ltd. China

Dental X-ray System

🇹🇼 Avita Corporation — Taiwan

AViTA Breast Pump

🇨🇳 Shenzhen Magnet Technology Co., Ltd. — China

Bone Conduction Hearing Aid (3 models)

🇨🇳 Nagy Oral Technology Qinhuangdao Co., Ltd. — China

Fluoride Varnish (Type A, Type C)

🇰🇷 Hass Corp. — South Korea

Rosetta SM, Rosetta SP

🇯🇵 Hitachi High-Tech Corp. — Japan

PROBEAT-CR

💊 Drug Approvals

1 new drug approvals this week (1 NMEs). 5 efficacy supplements. 17 generics (ANDA).

New Drug Approvals (NDA / BLA)

VELIGROTUG LUMVOA **NME** **Priority Review** VIRIDIAN THERAPEUTICS INC

WHAT IT IS

Novel PDGFRα inhibitor; IV infusion; FDA Priority Review.

WHY IT MATTERS

As a new molecular entity for thyroid eye disease, this approval positions Viridian as a potential challenger to Amgen's blockbuster TEPEZZA. Its commercial success will likely depend on demonstrating a more convenient dosing profile compared to the established intravenous incumbent.

New Indications (Efficacy Supplements)

LETROZOLE AND RIBOCICLIB KISQALI FEMARA CO-PACK

New Formulation **Priority Review** NOVARTIS

WHAT IT IS

This co-pack combines an aromatase inhibitor and a CDK4/6 inhibitor, administered orally, with FDA Priority Review.

Adults with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.

WHY IT MATTERS

This adjuvant approval for early breast cancer represents a major market expansion for Kisqali, moving it into a much larger patient population with longer treatment duration. It positions Novartis to directly challenge Eli Lilly's Verzenio for market leadership in this lucrative setting, where Pfizer's Ibrance previously failed.

RIBOCICLIB KISQALI New Formulation Priority Review NOVARTIS

WHAT IT IS

This CDK4/6 inhibitor is administered orally, with FDA Priority Review.

Adults with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence.

WHY IT MATTERS

This adjuvant approval for early breast cancer represents a major market expansion for Kisqali, moving it into a much larger patient population with longer treatment duration. It positions Novartis to directly challenge Eli Lilly's Verzenio for market leadership in this lucrative setting, where Pfizer's Ibrance previously failed.

ROFLUMILAST ZORYVE New Formulation ARCUTIS

WHAT IT IS

This selective phosphodiesterase-4 inhibitor is applied topically as a cream.

Adults and pediatric patients 9 years and older with seborrheic dermatitis.

WHY IT MATTERS

By securing a label expansion into the large atopic dermatitis market, Arcutis could significantly broaden Zoryve's revenue base beyond psoriasis. Its once-daily, steroid-free profile may position it as a competitive alternative to Pfizer's twice-daily Eucrisa and a potentially safer option compared to topical JAK inhibitors with boxed warnings.

RISANKIZUMAB-RZAA SKYRIZI New Formulation ABBVIE INC

WHAT IT IS

This IL-23 inhibitor, a humanized monoclonal antibody, is administered via subcutaneous injection.

Adults with moderately to severely active ulcerative colitis.

WHY IT MATTERS

This approval in ulcerative colitis is a critical component of AbbVie's strategy to transition its immunology franchise from the biosimilar-exposed Humira to Skyrizi. Expanding into another major IBD indication is expected to help defend AbbVie's market leadership and capture share from competitors like Johnson & Johnson's Stelara.

VIMSELTINIB ROMVIMZA **New Formulation** DECIPHERA PHARMS

WHAT IT IS

This selective oral tyrosine kinase inhibitor targeting KIT and PDGFRα is administered orally.

WHY IT MATTERS

This approval positions Romvimza to potentially become the new standard of care for TGCT, as it enters the market without the severe liver toxicity warning that has limited the use of its only direct competitor, Turalio. For Deciphera, this provides a second commercial product and a significant opportunity to capture the majority of the market for this rare disease.

🩺 Medical Devices

510(k) clearances: **203** | PMA Original: **5** | Panel-Track: **2** | 30-Day Notice: **67**

PMA Approvals

AMDS Hybrid Prosthesis — Artivion, Inc.

> Cardiovascular prosthesis for surgical repair of aortic pathologies.

Centralized Lung Evaluation System (CLES) — Lung Bioengineering, Inc.

> Lung assessment system for evaluating donor lung viability prior to transplantation.

HepQuant SHUNT® Liver Diagnostic Test — Hepquant, LLC

> In vitro diagnostic test for assessing liver function and portosystemic shunting.

saypha® ChiQ™ — Croma-Pharma GmbH

> Dermal filler for improving skin smoothness and hydration.

VENTANA PTEN (SP218) RxDx Assay

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

> In vitro diagnostic assay for detecting PTEN protein expression as a companion diagnostic.

ETHIZIA Hemostatic Patch — ETHICON, Inc.

> Surgical hemostatic device for controlling bleeding during various surgical procedures.

SKINVIVE by JUVEDERM® — Allergan

> Dermal filler for improving skin smoothness and hydration.

510(k) Clearances (most recent 10)

Device	Applicant	Date
MIST IC Medical device - dental milling system for fabricating dental prosthetics.	Imagine Milling Technologies, LLC	2026-06-27

BraiN20® (BraiN20) Neurological monitoring device for assessing brain activity and function.	Time IS Brain, S.L.	2026-06-27
SOMNUM (SOMNUM) Sleep monitoring device for diagnosing and managing sleep disorders.	Honeynaps Co., Ltd.	2026-06-27
BioHorizons CEREC Compatible Ti-Bases Dental implant components for supporting CAD/CAM fabricated dental prosthetics.	BioHorizons Implant Systems, Inc.	2026-06-26
VERTICALE® Navigation Instruments Surgical navigation instruments for guiding orthopedic procedures.	Silony Medical GmbH	2026-06-26
PhAST instrument and PhAST Blood… In vitro diagnostic system for rapid identification of Gram-negative bacteria from blood cultures.	Phast Corp.	2026-06-26
i-STAT Crea cartridge with the i-STAT 1… Point-of-care diagnostic system for rapid measurement of creatinine in blood.	Abbott Point of Care, Inc.	2026-06-26
LightningWire Transseptal Puncture System Cardiac access system for performing transseptal punctures during electrophysiology procedures.	ElectroWire Medical	2026-06-26
Arterial Pressure Monitoring Set/Tray Vascular monitoring kit for continuous measurement of arterial blood pressure.	Spectrum Vascular	2026-06-26
Arthrex FiberButton Orthopedic fixation device for ligament and tendon repair in arthroscopic surgery.	Arthrex, Inc.	2026-06-26

* Full 203-item 510(k) dataset available in the Excel file attached to this issue.

⚠️ Warning Letters

Total this week: **13** | Significant (manufacturing/GMP): **0** | Unapproved/labeling: **13**

🔴 Drug Recalls

Product	Reason	Class
Lacosamide Tablets, USP, C V, 100mg, Rx only, 60-c	Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag	Class II
Corlanor (ivabradine) tablets, 7.5mg, 60-count bot	Presence of Foreign Substance.	Class II
Corlanor (ivabradine) tablets, 5 mg, packaged in a	Presence of Foreign Substance.	Class II
BD ChloraPrep Clear, (2% w/v chlorhexidine glucona	Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may b	Class II
Fenofibrate Capsules, USP 200 mg, Rx only, 100 Cap	CGMP Deviations	Class II
Sensipar (cinacalcet) Tablets, 60mg, 30-count bott	CGMP Deviations	Class II
Povi-One, 10% Povidone-Iodine Oral Antiseptic, Pac	sub potency	Class II
DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Ca	CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended	Class II
BD ChloraPrep FREPP Clear, (2% w/v chlorhexidine g	Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may b	Class II
Total Parental Nutrition - Pediatric PN Patient-Sp	Incorrect product formulation: bag did not contain copper and famotidine per lab	Class II

📋 FDA Guidance & Regulatory Actions

6 FDA regulatory documents this week.

Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (2026-07-09 • Notice)

This Notice states that TOVALT ODT (Zolpidem Tartrate) was not withdrawn for safety or effectiveness reasons. It affects generic drug manufacturers seeking to file ANDAs for this product.

Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec (2026-07-08 • Notice)

This Notice announces a public meeting and requests comments on BLA 125827 for Vusolimogene Oderparepvec. It affects biopharmaceutical companies developing cellular, tissue, and gene therapies.

Medical Device User Fee Amendments; Public Meeting; Request for Comments (2026-07-08 • Notice)

This Notice announces a public meeting and requests comments on the Medical Device User Fee Amendments. It affects the medical device industry, particularly manufacturers subject to MDUFA fees.

Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications (2026-07-06 • Notice)

This Notice announces the withdrawal of approval for 34 New Drug Applications from Endo Operations Limited and other companies. It affects the pharmaceutical industry, particularly the listed NDA holders.

Expedited Investigational New Drug Pilot Program; Request for Information; Correction (2026-07-06 • Notice)

This Notice provides a correction to a previous request for information on the Expedited Investigational New Drug Pilot Program. It affects pharmaceutical and biotechnology companies developing new drugs.

Determination That VASOPRESSIN IN SODIUM CHLORIDE (vasopressin) 0.9%, Injection, 50 units/50 milliliters (1 unit/milliliters) Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness (2026-07-06 • Notice)

This Notice states that VASOPRESSIN IN SODIUM CHLORIDE was not withdrawn for safety or effectiveness reasons. It affects generic drug manufacturers seeking to file ANDAs for this product.

For informational purposes only. Not legal, medical, or investment advice. See Terms of Use on final page.

© 2026 Troy Technical. All rights reserved.

🚫 **This report is licensed to the registered individual subscriber only. Forwarding, copying, or sharing this report or the attached Excel file is strictly prohibited.**

📜 Terms of Use & Disclaimer (Individual Plan)

Thank you for subscribing to **FDA Weekly Intelligence**. Please read the following terms carefully before using this report and any accompanying files.

1. Data Sources & AI-Assisted Generation

All data and information published in this report is sourced from official U.S. government publications, including the U.S. Food and Drug Administration (FDA) official website, the Federal Register, and the openFDA database.

To extract timely and actionable intelligence from large volumes of regulatory data, this report uses advanced generative AI (large language models) for data processing, summarization, and strategic commentary generation.

2. Accuracy & AI Hallucination Disclaimer

While we apply quality review processes after AI-assisted generation to minimize errors, the nature of machine learning models means that translation nuances, contextual misinterpretations, or inaccuracies may occasionally appear. We do not guarantee the 100% accuracy, completeness, timeliness, or fitness for a particular purpose of any information provided.

For decisions requiring verified regulatory information, always refer to the original English-language source documents published by the FDA.

3. No Professional Advice

This report provides general market intelligence for informational purposes only. It does not constitute and should not be relied upon as:

- **Regulatory or legal advice:** Not a substitute for qualified legal or regulatory counsel regarding FDA submissions, compliance, or enforcement matters.
- **Investment advice:** Not a recommendation to buy, sell, or hold any security, or to pursue any M&A or licensing transaction.
- **Medical advice:** Not intended to guide clinical decisions by healthcare professionals or patients.
- **Drug or device recommendation:** This report summarizes FDA's publicly announced approvals, clearances, warning letters, and other enforcement actions. It does not recommend, endorse, or make any representation regarding the efficacy, safety, or superiority of any specific drug or medical device.

The publisher accepts no liability for any direct or indirect loss, including lost profits, business interruption, or consequential damages, arising from reliance on the information in this report. All decisions based on this report are made at the reader's own risk.

4. Copyright, Permitted Use & Sharing Policy (Individual Plan)

All intellectual property rights in this report and accompanying data files are owned by the publisher. To protect the value of this service, the following usage rules apply:

Permitted Use (Individual Subscriber)
Access to this report is granted solely to the registered individual subscriber. You may use data and insights from this report in your own professional work, including internal presentations, memos, and reports, provided you do not reproduce the report in its entirety.

Prohibited Use (Sharing & Redistribution)
Forwarding or distributing this report (HTML, PDF, or Excel) to colleagues, clients, or any third party is strictly prohibited. Sharing login credentials or account access with others is also prohibited. Publishing any portion on websites or social media, or reselling this content, is not permitted. Violations may result in immediate termination of service and claims for damages.

5. Subscription, Auto-Renewal & Refund Policy

Subscription & Auto-Renewal Disclosure: This is a recurring subscription service. Your subscription will automatically renew at the end of each billing period, and your payment method will be charged automatically unless you cancel before the renewal date. You will receive a reminder email prior to each renewal. To cancel, log in to your Gumroad or Substack account and cancel before the next billing date. Cancellation stops future charges but does not entitle you to a refund for the current period.

Refund Policy: Due to the digital nature of this product, refunds are not available once a report has been delivered or a billing period has commenced. If you believe you were charged in error, please contact us within 7 days at info@troy-technical.jp and we will review your case.

6. Privacy & GDPR Compliance

We collect and process only the personal data necessary to deliver this service (name, email address, and billing information). Your data is processed by our payment and delivery platforms (Gumroad and/or Substack) in accordance with their respective privacy policies. We do not sell or share your personal data with third parties for marketing purposes.

If you are a resident of the European Economic Area (EEA) or the United Kingdom, you have the following rights under the General Data Protection Regulation (GDPR) and applicable UK data protection law:

- **Right of access:** You may request a copy of the personal data we hold about you.
- **Right to rectification:** You may request correction of inaccurate personal data.
- **Right to erasure:** You may request deletion of your personal data, subject to our legal obligations to retain certain records.
- **Right to object / restrict processing:** You may object to or request restriction of processing of your personal data in certain circumstances.
- **Right to data portability:** You may request a machine-readable copy of your data.

To exercise any of these rights, please contact us at info@troy-technical.jp. We will respond within 30 days. You also have the right to lodge a complaint with your local data protection authority.

The legal basis for processing your personal data is the performance of a contract (delivery of the subscription service you have purchased).

7. Limitation of Liability

To the maximum extent permitted by applicable law, the publisher's total liability to you for any claim arising out of or in connection with this service shall not exceed the total subscription fees paid by you in the three (3) months preceding the claim. In no event shall the publisher be liable for any indirect, incidental, special, consequential, or punitive damages, including but not limited to loss of profits, loss of data, or business interruption, even if advised of the possibility of such damages.

8. Dispute Resolution & Governing Law

These Terms are governed by the laws of Japan, without regard to its conflict of law provisions. Any dispute, controversy, or claim arising out of or relating to these Terms or the service shall first be attempted to be resolved through good-faith negotiation. If not resolved within 30 days, the dispute shall be finally settled by binding arbitration administered by the Japan Commercial Arbitration Association (JCAA) under its Commercial Arbitration Rules. The arbitration shall be conducted in English, in Tokyo, Japan. The arbitral award shall be final and binding on both parties.

Nothing in this section shall prevent either party from seeking urgent injunctive or other equitable relief from a court of competent jurisdiction to prevent irreparable harm.

9. Service Continuity Statement

The core functionality of this service relies heavily on third-party generative AI (large language model) services. If the supply policies, pricing structure, or terms of use of such third-party services change materially, or if such services are discontinued or become unavailable, such that the quality, cost structure, or operation of this service can no longer be reasonably maintained, the publisher reserves the right to **suspend or terminate this service**. If termination becomes necessary, subscribers will be notified by email at least 30 days in advance, and any fees already collected for undelivered subscription periods will be refunded on a pro-rata basis. The publisher will use reasonable efforts to maintain service stability but does not guarantee that this service will continue indefinitely.

10. Changes to These Terms

We reserve the right to update these Terms at any time. Material changes will be notified to subscribers by email at least 14 days before taking effect. Continued use of the service after the effective date of any changes constitutes your acceptance of the revised Terms.

© 2026 Troy Technical. All rights reserved. / Publisher: Troy Technical / Last updated: June 28, 2026 / Contact: info@troy-technical.jp